Hikma Pharmaceuticals USA Inc. received FDA approval for its Abbreviated New Drug Application (ANDA) covering oral Eltrombopag Olamine on April 8, 2026, positioning the company to capture market share from branded competitors in the treatment of severe aplastic anemia and related conditions.